Navigation Links
Weekly Digest's Investor Essentials Special Report Identifies Unique Investing Opportunities in the H1N1 'Swine Flu' Outbreak
Date:10/14/2009

PRINCETON, N.J., Oct. 14 /PRNewswire/ -- Weekly Digest (http://www.bullmarket.com/digest), a free investment research publication, announced the publication of a special report on investment opportunities in the connection with the H1N1 "Swine Flu" Outbreak, including updated outlooks for Gilead Sciences (Nasdaq: GILD), Sinovac Biotech (Amex: SVA), Dynavax Technologies (Nasdaq: DVAX), Hemispherx BioPharma (Amex: HEB), BioCryst Pharmaceuticals (Nasdaq: BCRX) and several others.

After posting large gains throughout 2009, swine flu stocks are seeing their largest pullback yet. For investors looking to position their portfolios for flu season, there are more ways to trade the flu than ever. Investors have large-cap pharmaceutical plays to choose from, and some of the more volatile, small-cap names have proven the efficacy of their drugs, while others are too far behind in their clinical trials to capitalize on the current pandemic.

To receive a free, 23-page report offering in depth analysis of the various participants in the vaccine and antiviral market, as well as some peripheral plays focusing directly on the impact of the current H1N1 swine flu pandemic, please visit the following link:

http://www.bullmarket.com/digest/signup.php?refer=pr1_swineflu

The report covers these topics and more recent reports:

-- Which small-cap swine flu plays have a real chance of benefiting in the event of a serious H1N1 outbreak and which are riding on the hype?

-- What sets Sinovac apart from other small caps pursuing vaccines and treatments to fight swine flu? How robust is Sinovac's array of products?

-- Is BioCryst likely to see revenue from its flu treatment during this flu season? How does BioCryst's peramivir fare against established drugs Tamiflu and Relenza? What are the downside risks facing BioCryst after its strong run higher?

-- Is Dynavax a real swine flu play? What do Dynavax investors need to know about the company's swine flu efforts?

-- How important is Tamiflu to Gilead's business? What are the mechanics of Gilead's Tamiflu royalty arrangement with Roche? What are the threats to Tamiflu's dominance in the antiviral market?

About Weekly Digest:

Weekly Digest is a free publication offering first-rate stock research, analysis, and commentary that is independently published by leading investment services. Subscribers receive a weekly newsletter as well as regular Special Reports, such as the new report Investor Essentials: Picking Winners for Pandemic Profits.

NOTE: This release was published by Indie Research Advisors, LLC, a registered investment advisor with CRD #131926. Interested parties may visit adviserinfo.sec.gov for additional information. Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

CONTACT: Marcia Martin, +1-888-278-5515

SOURCE Indie Research Advisors, LLC


'/>"/>
SOURCE Indie Research Advisors, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Study Shows Once-Monthly Boniva(R) is as Clinically Effective as Once-Weekly Fosamax(R) at Increasing Bone Mineral Density in Postmenopausal Women With Osteoporosis
2. Type 2 Diabetes Patients Taking Exenatide Once Weekly, a Phase 3 Investigational Diabetes Therapy, Showed Improvements in Glycemic Control, Weight
3. After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008
4. (RED) to Launch New Way for People to Get Music in Their Lives; Weekly Delivery of Great Music Helps to Save Lives in Africa
5. Plans for Exenatide Once Weekly NDA Submission by End of First Half of 2009 Reaffirmed Following FDA Feedback
6. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
7. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
8. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
9. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
10. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
11. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , January 19, 2017 ... administration appears serious about reducing the FDA,s regulatory ... innovation in the medical drug industry, many of ... with new clinical trials and development of advanced ... forging ahead with recent developments include:  Moleculin Biotech, ...
(Date:1/19/2017)... 2017  Magnetic Insight Inc., leader in magnetic ... agreement with inviCRO LLC to develop intuitive image ... based on inviCRO,s VivoQuant™ visualization and post processing ... complete MPI solution package with the Momentum MPI ... imaging in vivo. MPI is a ...
(Date:1/18/2017)... 18, 2017  EnteroMedics Inc. (NASDAQ: ... neuroblocking technology to treat obesity, metabolic diseases and ... an underwritten public offering of units for gross ... discounts and commissions and offering expenses payable by ... Class A Units, priced at a public offering ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... 2017 , ... Tribble Insurance Agency, a family owned and operated firm offering ... charity event to honor Chad Phillip Dermyer, a local police trooper who was shot ... and his fellow officers were conducting routine stops of suspects when one of them, ...
(Date:1/19/2017)... ... January 19, 2017 , ... For the second consecutive year, ... Connecticut (RMACT) have earned “Top Doctor” awards. Dr. Mark Leondires, Dr. Spencer Richlin, ... been chosen by their peers for the 2017 list based on their exceptional ...
(Date:1/19/2017)... ... January 19, 2017 , ... Sales Focus Inc. (SFI), a Maryland-based sales ... market. , Over the past 20 years SFI has been recognized as the world’s ... six new clients into the US market. The new clients include: Panacea Pro, ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known ... Few people know that popular cosmetic fillers can enhance earlobes and ... medical director of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
Breaking Medicine News(10 mins):